Skip to main content

Table 5 Comparisons of LDLC change among PCSK9 inhibitor treatment groups and between statin tolerant and intolerant groups

From: Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study

  Alirocumab 75 mg (n = 25) Alirocumab 150 mg (n = 15) Evolucumab 140 mg (n = 32)
LS means ± SE of change in LDLC (mg/dl) −59 ± 10 −110 ± 14 −95 ± 9
 Group differences ALI 75 vs ALI 150, p = .004
ALI 75 vs EVO 140, p = .014
LS means ± SE of % change in LDLC (%) −42 ± 5% −63 ± 7% −56 ± 4%
 Group differences ALI 75 vs ALI 150, p = .011
ALI 75 vs EVO 140, p = .044
LS means ± SE of change in LDLC (mg/dl) −109 ± 7 −78 ± 5
Group differences p = .0008
LS means ± SE of % change in LDLC (%) −63 ± 5% −48 ± 4%
Group differences p = .013
  1. LS means for 3 treatment groups, adjusted for treatment duration, age, BMI, race, gender, statin intolerance (yes-no), HeFH (yes-no), and CVD (yes-no)
  2. LS means for statin tolerant vs intolerant groups, adjusted for PCSK9 groups, treatment duration, age, BMI, race, gender, HeFH (yes-no), CVD (yes-no) and LDLC at entry